Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03906045 | A Scintigraphy Study of PT010 in COPD Patients | PHASE1 | COMPLETED | 18 | — | — | Apr 4, 2019 | Mar 5, 2020 | Feb 12, 2021 | 2 | United Kingdom |
Percentage of BGF MDI deposited in the lungs.
| Arm | Type | Description |
|---|---|---|
| All patients | EXPERIMENTAL | 10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds. |
| Name | Type | Description |
|---|---|---|
| BGF-MDI | DRUG | Budesonide, Glycopyrronium and Formoterol Fumarate. |
Main Inclusion Criteria: * Males and females at least 40 years of age and no older than 80 years. * Patients with diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) \[1\]. * Post bronchodilator (BD) FEV1 / Forced Vital Capacity (FVC) ratio must...